Announcing Granite's CM/GC Rehabilitation and Construction Project at SFO
Project Timeline:
Major Construction: March 2026 through November 2026
The project will rehabilitate Runway 1R-19L and construct Taxiway W between Taxiway A and Taxiway L. It includes upgrades to the hot mix asphalt pavement, lighting infrastructure, drainage, signage, Runway Status Lights (RWLS), sectionals, grooving, and striping. The existing Taxiway F1 will be demolished, and a new Taxiway W will be constructed.
'We are committed to building a lasting collaboration with SFO and all stakeholders to deliver this critical infrastructure efficiently and effectively, while minimizing disruptions for both employees and SFO passengers,' said Granite Vice President of Regional Operations Brent Fogg. 'We are honored to partner with the exceptional SFO team to enhance the airfield and uphold SFO's reputation as the Best Airport in North America.'
Granite will supply asphalt from its Santa Clara Asphalt facility, approximately 185,000 tons of P401 and P403 Mix.
The total anticipated construction value is estimated at $115 million and was included in Granite's second-quarter CAP. The project is expected to begin in March 2026 and continue through November 2026.
About Granite
Granite is America's Infrastructure Company™. Incorporated since 1922, Granite (NYSE:GVA) is one of the largest diversified construction and construction materials companies in the United States as well as a full-suite civil construction provider. Granite's Code of Conduct and strong Core Values guide the Company and its employees to uphold the highest ethical standards. Granite is an industry leader in safety and an award-winning firm in quality and sustainability. For more information, visit the Granite website, graniteconstruction.com, and connect with Granite on LinkedIn, X, Facebook, and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Josh Brown's New Best Stock Idea: a South Korean Ecommerce Company
Coupang, Inc. (NYSE:CPNG) is one of the . Josh Brown, CEO of Ritholtz Wealth Management, recently pitched Coupang as one of the best stocks during a program on CNBC. Here is why Brown likes the stock. "Coupang Inc (NYSE:CPNG) is on the best stocks in the market list because it's a Korean business but it's incorporated and based in Seattle. So this is a US company with a US founder, but most of their business is being the Amazon of South Korea. The best comp here is MercadoLibre. MELI is up 9,000% plus since its IPO. This company is probably 5 years behind MELI in terms of its margins, its earnings, its growth. So there's still a lot of opportunity. It came public in '21. Everybody forgot about it because the whole growth stock market crashed for a year. But now it's working its way back, and the reality is that it's not terribly expensive. It's in a 40% drawdown from that '21 high. Barclays has a $36 target, and it's a best stock. It's breaking out. You've got a 50- to 200-day moving average crossover, which signals short-term momentum, and I think the stock probably gets itself into the mid-30s at a minimum based on the breakout that we've seen." Photo by Mohamed Hadji on Unsplash Baron Fifth Avenue Growth Fund stated the following regarding Coupang, Inc. (NYSE:CPNG) in its Q4 2024 investor letter: 'Shares of Coupang, Inc. (NYSE:CPNG), Korea's largest e-commerce platform, corrected 10.5% in the fourth quarter (even though they finished 2024 up 33.9%). While the company delivered solid quarterly results with 27% year-on-year revenue growth with Farfetch and other initiative losses narrowing significantly, its product commerce EBITDA margin missed expectations due to a temporarily elevated spending on technology and automation. Sluggish domestic consumption in Korea, with the e-commerce market experiencing flattish to negative growth, and political uncertainty stemming from President Yoon's declaration of martial law and subsequent impeachment, further weighed on the stock. Despite these short-term challenges, we maintain a positive outlook on Coupang's long-term market share expansion and margin growth trajectory, and view Coupang as one of the most competitively advantaged e-commerce businesses globally, with significant runway for both revenue and earnings growth.' While we acknowledge the potential of CPNG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Analyst Explains Why Uber Technologies (UBER) Stock Can Grow More Despite 50% Year-to-Date Gains
Uber Technologies, Inc. (NYSE:UBER) is one of the . Mark Mahaney, Evercore ISI head of internet research, explained in a recent program on CNBC that Uber Technologies (NYSE:UBER) needs to expand in more geographies for growth via partnerships 'If you get more of these rollouts with Waymo, and you get other AV companies—there's more than just, you know, it's not just Waymo's world and it's not just Tesla's world. And by the way, of those two, Waymo is dramatically better in terms of what they've been able to show and roll out so far. But if you get Zoox in the market, and then you get a couple of Chinese players—not in the US but in parts of the Middle East, maybe in Europe—and if you get more companies like Mobileye, Mobilewave, if you get these companies out there showing that you can get multiple AV vendors, maybe not two or three but maybe four, five, or six, that's better for Uber's economics.' The analyst thinks there's still more room for Uber Technologies (NYSE:UBER) stock to grow: 'I think there's a lot more room for Uber stock. I know it's up 50% year to date, but this thing trades at like 18–19 times free cash flow. It should trade at 25 times free cash flow. They're growing their free cash flow 25% to 30%.' Hinde Group stated the following regarding Uber Technologies, Inc. (NYSE:UBER) in its Q1 2025 investor letter: 'With operations in more than 10,000 cities across 72 countries and gross bookings expected to exceed $180 billion this year, Uber Technologies, Inc. (NYSE:UBER) is one of the largest transportation network companies in the world. Each month, Uber helps more than 170 million users meet their mobility and delivery needs by connecting them with more than 7 million independent drivers and couriers. Uber's mobility and delivery services are enabled by a highly sophisticated and efficient technology platform that automatically manages and optimizes demand prediction, matching & dispatching, routing, pricing, and personalization, among other functions. Uber has a leading category position in eight of its top ten mobility and delivery markets. While we acknowledge the potential of UBER as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Wire
20 minutes ago
- Business Wire
Geneticure Inc. Granted New U.S. Patent for Genetic Test to Predict Response in Renal Denervation for Hypertension
ROCHESTER, Minn.--(BUSINESS WIRE)--Geneticure Inc., a leader in precision medicine for cardiovascular disease, announced today that the United States Patent and Trademark Office has granted U.S. Patent No. 12,351,873, for a Genetic-Based Weighted Algorithm Model for Predicting Response to Renal Denervation. This groundbreaking patent protects Geneticure's proprietary method of using a patient's genetic profile to predict their likelihood of benefiting from renal denervation — a minimally invasive procedure used to treat hypertension. 'Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other's experiencing no change or an increase in blood pressure post-denervation.' said Scott Snyder, CEO of Geneticure. Share 'Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other's experiencing no change or an increase in blood pressure post-denervation.' said Scott Snyder, CEO of Geneticure. 'Prior to Geneticure's research, a reliable method of predicting the response had not yet emerged and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage.' The patented method leverages specific genetic markers combined with a proprietary weighted algorithm to determine responsiveness to renal denervation, enabling physicians to make informed treatment decisions beyond traditional risk-factor assessments. This newly issued patent expands Geneticure's growing intellectual property portfolio in the field of pharmacogenomics and device response prediction, further positioning the company at the forefront of personalized hypertension management. More on Geneticure for Renal Denervation: About Geneticure Geneticure Inc. is an Integrated Computational Genomic medicine company focused on eliminating the trial-and-error approach to treating chronic diseases. By integrating a patient's genetic information with physiologic insights, Geneticure provides physicians with actionable tools to optimize therapy selection and improve outcomes. The company's flagship offerings include genetic tests that predict response to common hypertension medications and now, response to renal denervation.
